CONFIDENTIAL



Health Economics Research Centre

A RANDOMISED CONTROLLED TRIAL OF ALTERNATIVE TREATMENTS TO INHIBIT VEGF IN AGE-RELATED CHORIODAL NEOVASCULARISATION (IVAN)

Operating Cost Questionnaire

Additional staff providing information:

Contact Name:
Job Title:
Email Address:
Question(s) completed:
Contact Name:
Job Title:
Email Address:
Question(s) completed:
Contact Name:
Job Title:
Email Address:
Question(s) completed:

PLEASE DO NOT DETACH THIS PAGE

OPERATING COST QUESTIONNAIRE

Thank you for taking time to complete this questionnaire. Your answers will be kept confidential and will only be used for the IVAN study.

The aim of this research is to collect information on the costs and resources required to (a) administer intra-vitreal injections of ranibizumab or bevacizumab for the treatment of neovascular age-related macular degeneration (nAMD) and (b) monitor outcomes in patients who have received ranibizumab or bevacizumab at any point in the past 2 years.

The information that you provide on this questionnaire is essential for us to assess the cost-effectiveness of ranibizumab or bevacizumab and the cost-effectiveness of the continuous and discontinuous therapy regimens evaluated in IVAN.

Notes on filling in the questionnaire:

- We are interested in the cost of treatment/monitoring in <u>routine clinical</u> practice, *not* the cost of IVAN clinics.
- This questionnaire should be completed by someone (e.g. a clinic manager)
 who is involved in running NHS clinic sessions in which
 ranibizumab/bevacizumab are given or in which patients are monitored
 following ranibizumab/bevacizumab treatment.
- If you don't know the answer to any given question, please complete all questions that you can answer and pass the questionnaire on to others at your centre so that they can complete additional sections. If nobody at your centre has the information required to answer a particular question, please give your best guess wherever possible and otherwise leave it blank and complete and return the remainder of the questionnaire.
- Please write "0" in response to any questions to which the answer is zero.
- All costs should <u>include VAT</u>. If you prefer to give costs excluding VAT, please state clearly which costs exclude VAT.

receiving ranibizumab/bevacizumab on the NHS (outside of clinical trials)?
(please tick (✓) or underline the appropriate option)
A one-stop service in which monitoring and investigations for patients who have received ranibizumab/bevacizumab are conducted in the same clinic as ranibizumab/bevacizumab is administered.
Separate monitoring and treatment clinics run on <i>different</i> days, whereby patients attend the clinic for monitoring/investigations on a separate occasion from their intra-vitreal ranibizumab/bevacizumab injections.
Separate monitoring and treatment clinics run on the <i>same</i> day: e.g. a monitoring clinic run in the morning, followed by a treatment clinic in the afternoon of the same day.
A mixture of the first three options. (If you ticked this option, please answer the questions below)
a) What proportion of patients receiving intra-vitreal ranibizumab/bevacizumab injections attend one-stop clinics?
What determines whether a patient attends a one-stop clinic?
None of these options (If you ticked this option, please provide details)

1a. Which of the following 5 options best describes the clinics you run for patients

- 1b. Please give details of all of the clinic sessions that you regularly run which involve either:
 - Administration ranibizumab/bevacizumab to at least one patient (excluding trial participants)

AND/OR

• Monitoring of one or more patients who have received ranibizumab or bevacizumab in the last 2 years (excluding trial participants).

Please exclude clinic sessions that are run specifically for trial participants, but include clinics in which some patients are enrolled in clinical trial(s) and others are receiving ranibizumab/bevacizumab in routine clinical practice.

Please write "0" in response to any questions to which the answer is zero instead of leaving such cells blank.

Please estimate patient numbers or proportions if these statistics are not collected.

Your name for this clinic	What is provided in this clinic (e.g. monitoring of nAMD pts, administration of	Length of clinic (hours)	Frequency with which it is run (e.g. weekly)	atten	l no. p ding tl		bevaciz	s who r	eceive b/	attende previou ranibizuma but are <u>N</u>		nave ived izumab	% of clinic attendees enrolled in clinical	clinic that share tendees facilities (e.g.	
	or ranibizumab/ bevacizumab)		weekiy)	Mean (average)	Min	Max	Mean (average)	Min	Max	Mean (average)	Min	trials Max	trials	No. clinics	Total no. pts
A1: Injection co	linics in which <u>m</u> essment	ost patiei	nts receive in	tra-vitre	al ran	ibizum	ab or bevo		ab <u>with</u>	out also und	dergoing	g OCT, I		tailed	
							%	%	%	%	%	%	%		
							%	%	%	%	%	%	%		
							%	%	%	%	%	%	%		

Your name for this clinic	What is provided in this clinic (e.g. monitoring of nAMD pts, administration of	Length of clinic (hours)	Frequency with which it is run (e.g. weekly)	atten	l no. p ding th		bevaciz	who re	eceive b/	attende previou ranibizuma but are <u>N</u>		nave ived izumab	% of clinic attendees enrolled in clinical	run af same that s facilitie OCT/	Other clinics run at the same time that share facilities (e.g. OCT/FFA rooms)	
	ranibizumab/ bevacizumab)			Mean (average)	Min	Max	Mean (average)	Min	Max	Mean (average)	Min	Max	trials	No.	Total no. pts	
			S. 4. 11. 1		rocoin	od ran	ibizumobo	nd/or h	evacizi	ımah in the	last 2 vo	ars hut i	n which no r	ts receiv	re	
A2: Review/mor ranibizumab or	nitoring clinics att bevacizumab toda	-	21 patients v	vno nave	receiv	eu ran	IDIZUIIIAD d	na/or b	CVUCIZU	imas in the	ust z yc	uro but n	wο <u>ο</u> μ	10 100011		
	_	-	21 patients v	vno nave	receiv	eu ran	0%	0%	0%	%	%	%	%	100011		
	_	-	21 patients v	vno nave	receiv	eu ran										
	_	-	21 patients v	vno nave	receiv	eu ran	0%	0%	0%	%	%	%	%			
ranibizumab or	_	ay					0%	0%	0%	%	%	%	% %			
ranibizumab or	bevacizumab toda	ay					0%	0%	0%	%	%	%	% %			
ranibizumab or	bevacizumab toda	ay					0% 0% 0% an intra-vi	0% 0% 0%	0% 0% 0%	% % of ranibizum	% % ab or be	% % %	% % %			

C: Other clinics that do not fit into the above categories but which are attended by (a) ≥1 patients who have received ranibizumab and/or bevacizumab in the last 2 years and/or (b) ≥1 patients who will be given ranibizumab or bevacizumab in this clinic

Your name for this clinic	monitoring of nAMD pts, administration	Length of clinic (hours)	Frequency with which it is run (e.g.	atten	l no. p ding t		bevaciz	s who r	eceive b/	attende previou ranibizuma but are <u>N</u>		have ived izumab	% of clinic attendees enrolled in clinical	Other of run at same that s facilities OCT/	t the time hare s (e.g. FFA
	of ranibizumab/ bevacizumab)		′ weekly)	Mean (average)	Min	Max	Mean (average)	Min	Max	Mean (average)	Min	Max	trials	No. clinics	Total no. pts
							%	%	%	%	%	%	%		
							%	%	%	%	%	%	%		
	EEA fundus fluoross						%	%	%	%	%	%	%		

Abbreviations: FFA, fundus fluorescein angiography; OCT, optical coherence tomography.

If there was insufficient space in the table, please give further details of your clinics or the way in which they are run here.

2. Rooms and staff required to run each type of clinic

Question 3 should be answered for each of the 4 types of clinic defined in Question 3 that apply to your centre.

- If you run separate injection/monitoring clinics, please give details of your injection clinics in Q3A1 (pages 7-8) and your monitoring clinics in Q3A2 (pages 9-10)
- If you run one-stop clinics, please give details of these in Q3B (pages 11-12)
- If you run any other types of clinic for ranibizumab/bevacizumab patients, please give details of these in Q3C (pages 13-14).

Please note that we are primarily interested in usual care clinics, rather than those run specifically for clinical trials.

- o If you run separate clinics *exclusively* for patients participating in clinical trials you do **not** need to describe the trial clinics here.
- However, please do give details of clinics in which some but not all patients are enrolled in clinical trial(s).

If any of these 4 categories include clinics that require very different numbers of staff or rooms, please complete the questionnaire separately for each type of clinic that uses a different amount of resource use or requires a different number of staff, by printing out extra copies of these pages or by copying and pasting the relevant questions later in this Word document. For example, if you run 2 one-stop clinics each week, with 5-15 patients being seen at the smaller clinic and 20-40 being seen at the larger clinic, please fill in Question 2B separately for each clinic, recording your answers for your small one-stop clinic on pages 7-8 and answers for the large one-stop clinic on a different sheet.

If you have used any continuation sheets for this question, how many continuation
sheets have you used?
If you have used continuation sheets, please record below which clinics are described
in each section (using the clinic names that you specified in Q3):
A1 (Injection clinics):
A2 (Review clinics):

3 (One stop clinics):	
C (Other clinics):	
Continuation sheet 1:	
Continuation sheet 2:	
(1) <u>Injection clinic(s)</u> in which <u>most</u> patients receive an intra-vitreal injection of	
anibizumab or bevacizumab without also undergoing OCT, FFA or a detailed	
ptometric assessment	

- i) How long does the average patient spend in the clinic at each visit?hours
- ii) Please provide details of the rooms that are used in each clinic session for your injection clinic(s).

If necessary, please give a range of values or complete this question separately for different types/sizes of injection clinic.

Name of room	Number of rooms of this type used per clinic session by pts who have had ranibizumab/ bevacizumab	Number of patients who have had/are having ranibizumab/ bevacizumab who use this type of room in the average clinic session	Number of other patients who use this type of room in the average session when your injection clinic is run (including pts attending other clinics running at the same time)
Sterile room(s)			
where injection is			
administered			
OCT room(s) or			
machine(s)			
FFA room(s) or			
machine(s)			
Visual testing lanes			
Consulting room(s)			
Optometric			
assessment room(s)			
Waiting area(s)			
Recovery room(s)			
Other (please specify)			

Abbreviations: FFA, fundus fluorescein angiography; OCT, optical coherence tomography.

iii) List in the table below all the staff who are involved in your injection clinic(s) each time they are run.

If necessary, please give a range of values or complete this question separately for different types/sizes of injection clinic.

clinic during an		n, two of	whom are also ir	Role(s) in clinic hree Grade 5 nurse		
EXAMPLE -	Staff nurse	5	Treatment	Helping with intra-	1	100%
NURSES			room	vitreal injections		
	Staff nurse	5	Various	Running clinic, visual testing, fluorescein injections	2	50%
	l for your clinic					
Nurses						
Healthcare						
assistants						
Oliviai						
Clinicians						

Staff type	Post	Grade /band	Room in which he/she is based	Role(s) in clinic	Number of staff (e.g. no. clinicians) involved in injection clinic	Proportion of their time during this clinic session that is spent on the injection clinic (rather than other clinics running at the same time)
Optometrists						
Ophthalmic						
photo-						
graphers/ technicians						
Administrative						
coordinators						
Data						
collection &						
management support staff						
Other						
administrative						
staff						
Eye clinic						
liaison officers						
Other (please						
specify)						
						A 1000 1000 1000 1000 1000 1000 1000 10

A2) <u>Mo</u>	<u>nitoring clinic(s)</u> attended by one or more patients who have received
ran	aibizumab and/or bevacizumab in the last 2 years but in which $\underline{\mathbf{no}}$ pts
rec	eive ranibizumab or bevacizumab injections

i)	How long does	the average i	oatient spend	in the clinic	at each visit?	hours

ii) Please provide details of the rooms that are used in each clinic session for your **monitoring clinic(s)**.

If necessary, please give a range of values or complete this question separately for different types/sizes of monitoring clinic.

Name of room	No. rooms of this type used per clinic session by pts who have had ranibizumab/bevacizumab	No. patients who have had/are having ranibizumab/bevacizumab who use this type of room in the average clinic session	No. other patients who use this type of room in the average session when your monitoring clinic is run (including pts attending other clinics running at the same time)
Sterile room(s)			
where injection			
is administered			
OCT room(s)			
or machine(s)			
FFA room(s) or			
machine(s)			
Visual testing			
lanes			
Consulting			
room(s)			
Optometric			
assessment			
room(s)			
Waiting area(s)			
Recovery room(s)			
Other (please			

specify)		

Abbreviations: FFA, fundus fluorescein angiography; OCT, optical coherence tomography.

iii) List in the table below all the staff who are involved in your monitoring clinic(s) each time they are run.

If necessary, please give a range of values or complete this question separately for different types/sizes of monitoring clinic.

Staff type	Post	Grade /band	Room in which he/she is based	Role(s) in clinic	No. staff (e.g. no. clinicians) involved in monitoring clinic	Proportion of their time during this clinic session that is spent on the monitoring clinic (rather than other clinics running at the same time)
Nurses						
Healthcare						
assistants						
Clinicians						

Staff type Optometrists	Post	Grade /band	Room in which he/she is based	Role(s) in clinic	No. staff (e.g. no. clinicians) involved in monitoring clinic	Proportion of their time during this clinic session that is spent on the monitoring clinic (rather than other clinics running at the same time)
Ophthalmic photo-graphers/technicians						
Data collection & management support staff Other						
administrative staff Eye clinic liaison officers						
Other (please specify)						

B)	One stop clinic(s) during which most patients receive both monitoring (e.g.
	OCT, FFA and/or a detailed optometric assessment) AND an intra-vitreal
	injection of ranibizumab or bevacizumab

i	How long does	the average patien	t spend in the	clinic at each	visit?hours

ii) Please provide details of the rooms that are used in each clinic session for your <u>one</u> stop clinic(s).

If necessary, please give a range of values or complete this question separately for different types/sizes of one-stop clinic.

Name of room	No. rooms of this type used per clinic session by pts who have had ranibizumab/bevacizumab	No. patients who have had/are having ranibizumab/bevacizumab who use this type of room in the average clinic session	No. other patients who use this type of room in the average session when your one stop clinic is run (including pts attending other clinics running at the same time)
Sterile room(s)			
where injection			
is administered			
OCT room(s) or			
machine(s)			
FFA room(s) or			
machine(s)			
Visual testing			
lanes			
Consulting			
room(s)			
Optometric			
assessment			
room(s)			
Waiting area(s)			
Recovery			
room(s)			
Other (please specify)			

iii) L ti II	ist in the table bel	ow all th	e staff who are	CT, optical coherence involved in your of	one stop clinic(
Staff type	Post	Grade /band	Room in which he/she is based	Role(s) in clinic	No. staff (e.g. no. clinicians) involved in 1-stop clinic	Proportion of their time during this clinic session that is spent on the 1- stop clinic (rather than other clinics running at the same time)
xample of ho	w to complete the ta	ble for G	rade 5 nurses if t	hree Grade 5 nurse	s will be involve	d in your one stop
ŭ	y given clinic sessio he clinic session on	•		nvolved in other clini	cs run at the sa	me time and spend
VAADLE	C+- ((E	To a street of	I I - In in a social a factor -	1	100%

EXAMPLE - NURSES	Staff nurse	5	Treatment room	Helping with intra- vitreal injections	1	100%
	Staff nurse	5	Various	Running clinic, visual testing, fluoroscein injections	2	50%
Staff required	for your clinic					
Nurses						
Healthcare assistants						

Staff type	Post	Grade /band	Room in which he/she is based	Role(s) in clinic	No. staff (e.g. no. clinicians) involved in 1-stop clinic	Proportion of their time during this clinic session that is spent on the 1- stop clinic (rather than other clinics running at the same time)
Clinicians						
Optometrists						
Ophthalmic photo-						
graphers/						
technicians						
Administrative coordinators						
Data collection &						
management support staff						
Other						
administrative						
staff						
Eye clinic						
liaison officers						
Other (please specify)						

C) Other clinic(s) that don't fit into the above categories but which are attended by (a) one or more patients who have received ranibizumab and/or bevacizumab in the last 2 years AND/OR (b) one or more patients who will be given ranibizumab or bevacizumab in this clinic

If necessary, please use continuation sheets to give details of different types of clinic falling into this category.

- i) How long does the average patient spend in the clinic at each visit?hours
- ii) Please provide details of the rooms that are used in each clinic session for your **other clinic(s)**.

If necessary, please give a range of values or use the continuation sheets to complete this question separately for different types/sizes of clinic.

Name of room	No. rooms of this type used per clinic session by pts who have had ranibizumab/bevacizumab	No. patients who have had/are having ranibizumab/bevacizumab who use this type of room in the average clinic session	No. other patients who use this type of room in the average session when your other clinic is run (including pts attending other clinics running at the same time)
Sterile room(s)			
where injection			
is administered			
OCT room(s) or			
machine(s)			
FFA room(s) or			
machine(s)			
Visual testing			
lanes			
Consulting			
room(s)			
Optometric			
assessment			
room(s)			
Waiting area(s)			
Recovery			

room(s)		
Other (please specify)		

Abbreviations: FFA, fundus fluorescein angiography; OCT, optical coherence tomography.

iii) List in the table below all the staff who are involved in your other clinic(s) each time they are run.

If necessary, please give a range of values or use the continuation sheets to complete this question separately for different types/sizes of clinic.

Staff type Example of how	Post w to complete the t	Grade /band able for G	Room in which he/she is based	Role(s) in clinic three Grade 5 nurses	No. staff (e.g. no. clinicians) involved in other VEGF clinic	Proportion of their time during this clinic session that is spent on the other VEGF clinic (rather than other clinics running at the same time)
during any give	n clinic session, tw	o of whom	are also involv	ed in other clinics run	at the same tim	ne and spend around
half of the clinic	session on the inje	ection clini	C.			
EXAMPLE - NURSES	Staff nurse	5	Treatment room	Helping with intra- vitreal injections	1	100%
	Staff nurse	5	Various	Running clinic, visual testing, fluoroscein injections	2	50%
•••	for your clinic					
Nurses						
Healthcare						
assistants						

Staff type	Post	Grade /band	Room in which he/she is based	Role(s) in clinic	No. staff (e.g. no. clinicians) involved in other VEGF clinic	Proportion of their time during this clinic session that is spent on the other VEGF clinic (rather than other clinics running at the same time)
Clinicians						
Omnoidina						
Optometrists						
Ophthalmic						
photo-						
graphers/						
technicians						
Administrative						
coordinators						
Data						
collection & management						
support staff						
Other						
administrative						
staff						
Eye clinic						
liaison						
officers						
Other (please	_					
specify)						

3.	Are there any afternoons or mornings in which your clinic facilities are not used at
	all? (e.g. weekends or Friday afternoons)

YES/NO (please circle or underline the appropriate response to this and all subsequent yes/no questions)

a)	If YES , please state when your clinic facilities are not used at all:

a) Please provide details of average number of people using these facilities during clinic sessions in which <u>no</u> patients who have received ranibizumab or bevacizumab in the last 2 years are seen. Please note that we do not require a detailed breakdown for these clinics: simply an indication of how much these rooms are used at times when they are not being used by patients who have had ranibizumab/bevacizumab.

Name of room	Approximate number of rooms of this type used per clinic session	Approximate number of patients who use each room of this type in the average clinic session
Sterile room(s) where		
injection is		
administered		
OCT room(s) or		
machine(s)		
FFA room(s) or		
machine(s)		
Visual testing lanes		
Consulting room(s)		
Optometric		
assessment room(s)		
Waiting area(s)		
Recovery room(s)		
Other (please specify)		

4. Please indicate how often the assessments or procedures listed below are done and what facilities, staff and time is required each time.

For any tests that no patients will receive, please give the proportion as 0%.

If more than 50% of injections at your centre are done at one-stop clinics, please complete the third column (indicated by *) based on patients attending your one-stop clinic; otherwise, please complete this column based on patients attending your injection-only clinics.

Please record the tests and investigations that are done in routine clinical practice, NOT those required under the IVAN trial protocol.

Assessment	Approx proportion of clinic viperformed in routine Not clinic visits immediately before ranibizumab/			Room in which test is done	Staff conducting assessment (post and grade)	Approx time required for each test – inc preparation & updating notes (minutes)	
	ranibizumab/ bevacizumab is <u>initiated</u>	is administered*	in the last 2 yrs but who are <u>not</u> treated in this visit			If 1 eye tested	If both eyes tested
Example: All patients under	rgo Test A before	they start treatm	ent.				
If 100 patients receive ran	ibizumab/bevaciz	umab this month, a	round 50 of these patients will h	ave Test A before (o	r after) their injection.		
If 100 patients who have p	reviously had ranil	bizumab/bevacizum	nab attend monitoring-only visits	this month, around a	third of them will have Test A.		
Example: Test A	100%	50%	33%	Consulting room	Consultant	10	15
Assessment/consultation with clinician	%	%	%				

		•	visits in which this test is			Approx time required for each test – inc preparation & updating notes (minutes) If 1 If eye both tested eyes tested	
Assessment	Clinic visit immediately before ranibizumab/ bevacizumab is <u>initiated</u>	Clinic visits in which ranibizumab/ bevacizumab is administered*	Clinic visits by pts who have had ranibizumab/bevacizumab in the last 2 yrs but who are not treated in this visit	Room in which test is done	Staff conducting assessment (post and grade)		
Intra-ocular pressure	%	Before	%				
(IOP)		injection:% After injection:%					
Evaluating refraction	%	%	%				
Evaluating cylindrical and spherical correction	%	%	%				
Distance visual acuity using Snellen chart	%	%	%				
Distance visual acuity using LogMAR chart	%	%	%				
Near visual acuity (e.g. using Bailey Lovie)	%	%	%				

		•	visits in which this test is			Approx time required for each test – inc preparation & updating notes (minutes) If 1 If eye both tested eyes tested	
Assessment	Clinic visit immediately before ranibizumab/ bevacizumab is <u>initiated</u>	Clinic visits in which ranibizumab/ bevacizumab is administered*	Clinic visits by pts who have had ranibizumab/bevacizumab in the last 2 yrs but who are not treated in this visit	Room in which test is done	Staff conducting assessment (post and grade)		
Reading speed	%	%	%				
Contrast sensitivity	%	%	%				
FFA	%	%	%				
OCT	%	%	%				
Slit-lamp examination	%	%	%				
Dilated fundus examination	%	%	%				
Colour fundus photography	%	%	%				
Routine screen for changes in ocular motility	%	%	%				
Routine screen for eyelid/pupil responsiveness	%	%	%				

Assessment			Clinic visits by pts who have had ranibizumab/bevacizumab in the last 2 yrs but who are not treated in this visit	Room in which test is done	Staff conducting assessment (post and grade)	requir each te prepar upda no	ex time red for est – inc ation & ating tes utes) If both eyes tested
External examination of	%	%	%				
the eye and its adnexa							
Biomicroscopic examination	%	%	%				
Blood pressure	%	%	%				
Height measurement	%	%	%				
Weight measurement	%	%	%				
Other (please specify)	%	%	%				
	%	%	%				
	%	%	%				
	%	%	%				
	%	%	%				
	%	%	%				

5.	What staff are required in the treatment room while intra-vitreal injections of ranibizumab								
	or bevacizumab are being administered?								
	Please state post and grade for each role								
	a) How long are the treatment room and staff required for each patient receiving intra-								
	vitreal injection in one eye?								
	(Please <u>include</u> any time spent preparing or cleaning the room between uses and any time spent completing paperwork or electronic records relating to the injection.)								
	The room is required for minutes per injection								
	Nurse is required for minutes per injection								
	Ophthalmologist is required for minutes per injection								
	is required for minutes per injection								
	is required for minutes per injection								
	b) Would you consider giving intravitreal injections into both eyes during the same								
	clinic visit? YES / NO								
	i) If YES, please give details of how this would be done.								
	Please state: approximately what proportion of patients get often bilateral injections; whether the second injection would be given immediately or how long a gap would be left between injections; whether the patient would leave the treatment room between injections and (if not) how long the treatment room would be required for if both eyes were to be injected.								
6.	Are pre-prepared injection packs (containing the consumables and instruments required								
	for injection) used for the administration of ranibizumab or bevacizumab injections?								
	YES/NO								
	a) If YES , in approximately what proportion of injections are pre-prepared injection packs used%								

			No. minutes spent
Staff role	Post	Grade	per FFA conducted
			(including preparing patient for test)
Nurse(s)			passesses seed,
Healthcare assistants			
Tieatticale assistants			
Ophthalmic technician/			
photographer			
Clinician(s)			
Other (please specify)			
	any people live in the area		
	set up or modify in order ents?	to offer ranibi	
9. What facilities did you injections to NHS pati	set up or modify in order ents? Number of rooms of	to offer ranibi	zumab/bevacizumab
9. What facilities did you injections to NHS pati	set up or modify in order ents? Number of rooms of	to offer ranibi	zumab/bevacizumab you <u>set up</u> or <u>modifie</u> c
9. What facilities did you injections to NHS pati	set up or modify in order ents? Number of rooms of	to offer ranibi	zumab/bevacizumab you <u>set up</u> or <u>modifie</u> c
9. What facilities did you injections to NHS pati Room Waiting rooms Sterile rooms suitable for intra-vitreal injections	set up or modify in order ents? Number of rooms of	to offer ranibi	zumab/bevacizumab you <u>set up</u> or <u>modifie</u> c
9. What facilities did you injections to NHS pati Room Waiting rooms Sterile rooms suitable for	set up or modify in order ents? Number of rooms of	to offer ranibi	zumab/bevacizumab you <u>set up</u> or <u>modifie</u>
9. What facilities did you injections to NHS pati Room Waiting rooms Sterile rooms suitable for intra-vitreal injections	set up or modify in order ents? Number of rooms of	to offer ranibi	zumab/bevacizumab you <u>set up</u> or <u>modifie</u>
9. What facilities did you injections to NHS pati Room Waiting rooms Sterile rooms suitable for intra-vitreal injections Visual testing lanes	set up or modify in order ents? Number of rooms of	to offer ranibi	zumab/bevacizumab you <u>set up</u> or <u>modifie</u>
9. What facilities did you injections to NHS pati Room Waiting rooms Sterile rooms suitable for intra-vitreal injections Visual testing lanes OCT rooms	set up or modify in order ents? Number of rooms of	to offer ranibi	zumab/bevacizumab you <u>set up</u> or <u>modifie</u>
9. What facilities did you injections to NHS pati Room Waiting rooms Sterile rooms suitable for intra-vitreal injections Visual testing lanes OCT rooms FFA rooms	set up or modify in order ents? Number of rooms of	to offer ranibi	zumab/bevacizumab you <u>set up</u> or <u>modifie</u>
9. What facilities did you injections to NHS pati Room Waiting rooms Sterile rooms suitable for intra-vitreal injections Visual testing lanes OCT rooms FFA rooms Consultation rooms Optometric assessment rooms	set up or modify in order ents? Number of rooms of	to offer ranibi	zumab/bevacizumab you <u>set up</u> or <u>modifie</u> c
9. What facilities did you injections to NHS pati Room Waiting rooms Sterile rooms suitable for intra-vitreal injections Visual testing lanes OCT rooms FFA rooms Consultation rooms Optometric assessment	set up or modify in order ents? Number of rooms of	to offer ranibi	zumab/bevacizumab you <u>set up</u> or <u>modifie</u>

b) What is the cost per pre-prepared injection pack (including VAT)?

Abbreviations: FFA, fundus fluorescein angiography; OCT, optical coherence tomography.
10. What percentage (%) of 'On Costs' or 'overheads' does your trust charge?
c) Are overheads applied only to staff costs? YES/NO
d) If NO what ather recovers are such as decounted to 2
d) If NO , what other resources are overheads applied to?
11. Are there any other costs or resources that are required to run clinics for administering ranibizumab/bevacizumab or monitoring outcomes that you have not mentioned above?
ramoizumad/ocvacizumad of monitoring dutcomes that you have not mentioned above:
YES/NO
a) If YES , provide details below
12. If you have any comments on the questionnaire (such as difficulties that you encountered
interpreting or finding the information for any specific sections, or any suggestions you
may have for improving this questionnaire), please record them here.

THANK YOU FOR TAKING THE TIME TO COMPLETE THIS QUESTIONNAIRE